152 filings
Page 4 of 8
6-K
j4bmj790nxyt jogaar2
26 Apr 23
Report of Foreign Private Issuer
4:05pm
6-K
7kr0bmp2p
20 Apr 23
Report of Foreign Private Issuer
8:45am
6-K
gn6r1wx
17 Apr 23
Current report (foreign)
4:18pm
6-K
21abpgy9
17 Apr 23
Current report (foreign)
9:31am
424B5
9z7calijr fn
14 Apr 23
Prospectus supplement for primary offering
4:31pm
6-K
qea1n5ii0jcbh2zw h8o
14 Apr 23
Current report (foreign)
4:30pm
6-K
1c9 8qoz8k5
20 Mar 23
Report of Foreign Private Issuer
10:13am
6-K
j6goliy8iwvhed5
13 Feb 23
NeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts
9:27am
6-K
he1t4o4y1b4ftyeftpzg
9 Feb 23
NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases
9:25am
6-K
lq8 fp6wzh7r
8 Feb 23
NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial
9:18am
6-K
6gsk0
6 Feb 23
Report of Foreign Private Issuer
9:20am
EFFECT
i5xk4 24912hog
31 Jan 23
Notice of effectiveness
12:15am
UPLOAD
448czc4
26 Jan 23
Letter from SEC
12:00am
CORRESP
b8wi3cpr
26 Jan 23
Correspondence with SEC
12:00am
F-3
z9yr9 7mo
19 Jan 23
Shelf registration (foreign)
5:21pm
6-K/A
h7wd2l2znxu de0
19 Jan 23
NeuroSense Announces Second Quarter 2022 Financial Results and Provides Business Update
4:31pm
6-K
hiwyyduws4m7 3n7br
19 Jan 23
NeuroSense Therapeutics Reports Positive Final Results from Alzheimer’s Biomarker Study
9:15am
6-K
3rz x7g4icgvgx29j33
15 Dec 22
Report of Foreign Private Issuer
5:22pm
6-K
0iewqammswdhas1obh
1 Dec 22
NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update
9:26am